ERYPAR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erypar, and when can generic versions of Erypar launch?
Erypar is a drug marketed by Parke Davis and Warner Chilcott and is included in two NDAs.
The generic ingredient in ERYPAR is erythromycin stearate. There are one hundred and three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for ERYPAR
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 26 |
Patent Applications: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ERYPAR at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ERYPAR
US Patents and Regulatory Information for ERYPAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Parke Davis | ERYPAR | erythromycin stearate | TABLET;ORAL | 062032-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Parke Davis | ERYPAR | erythromycin stearate | TABLET;ORAL | 062032-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Warner Chilcott | ERYPAR | erythromycin stearate | TABLET;ORAL | 062322-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |